926536d5 4f6a 4c56 B05d 7e2149743ada 00
Xifaxan Tablet
Product Images NDC 55154-6777
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Xifaxan (NDC 55154-6777). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Cardinal Health 107, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Chemical Structure (Image 01)
Figure 1 (Image 02)
This is a figure that shows the proportion of patients without breakthrough HE over time (in days post-randomization) for XIFAXAN. The hazard ratio, confidence interval, and log-rank p-value are also provided.*
Figure 2 (Image 03)
This is a graphical representation showing the proportion of patients who didn't require hospitalization related to hepatic encephalopathy (HE) after being administered a placebo. The hazard ratio for this group was 0.5 with a 95% confidence interval of 0.287 to 0.873. The log-rank p-value was 0.00120. The chart shows data up to 168 days post-randomization.*
Bottle Label (Image 04)
This text seems to be a summary of medical treatment provided to a patient with a code name or identification number of "Cuil=BELENTEY". The treatment consisted of multiple phases named as "Phase 1", "Phase 2", etc. The patient was also given a symptom diary to record their symptoms daily or weekly. However, the text does not provide any information about the type of illness or symptoms the patient was experiencing.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
